Kalyanee Viraswami Appanna
About Kalyanee Viraswami Appanna
Kalyanee Viraswami Appanna is the VP Biometrics at Bristol Myers Squibb in New Jersey, United States, with over 20 years of experience in biostatistics within the pharmaceutical industry.
Title at Bristol Myers Squibb
Kalyanee Viraswami Appanna is currently serving as the Vice President of Biometrics at Bristol Myers Squibb. In this role, she is responsible for overseeing biostatistics and data analysis within the organization. Her work has a significant impact on the development and evaluation of new pharmaceutical products.
Previous Roles at Novartis
Before returning to Bristol Myers Squibb, Kalyanee Viraswami Appanna held several leadership roles in biostatistics at Novartis. She served as Executive Director of Biostatistics from 2013 to 2020, Director of Biostatistics from 2010 to 2013, and Senior Associate Director of Biostatistics from 2008 to 2010. During her tenure at Novartis, she enhanced the capacity and capability of biostatistics teams, contributing to various significant projects in the pharmaceutical sector.
Educational Background
Kalyanee Viraswami Appanna earned her Doctor of Philosophy (Ph.D.) in Statistics from the University of Toronto, where she studied from 1991 to 1994. Her academic background has provided a strong foundation for her career in biostatistics, enabling her to contribute effectively to her roles in the pharmaceutical industry.
Professional Experience in Biostatistics
With over 20 years of experience in biostatistics within the pharmaceutical industry, Kalyanee Viraswami Appanna has a comprehensive understanding of statistical analysis, drug development, and data interpretation. Her career includes key positions at Johnson & Johnson and multiple roles at Bristol Myers Squibb and Novartis, making her a seasoned expert in biostatistics leadership.
Specialization in Oncology Biostatistics
Kalyanee Viraswami Appanna has specialized in oncology biostatistics, leading teams in early development projects at Bristol Myers Squibb. Her work in this area has been instrumental in advancing the understanding of oncology treatments and improving the effectiveness of new therapeutic interventions.